Breaking News

Lilly to Acquire Loxo Oncology

Expands Lilly’s oncology portfolio into precision medicines with a marketed therapy and a pipeline of potential medicines for genomically defined cancers

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. and Loxo Oncology, Inc. have entered a definitive agreement for Lilly to acquire Loxo Oncology for approximately $8 billion in cash. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for genomically defined cancers. The acquisition is latest in a series of transactions Lilly has conducted to expand its cancer treatment efforts with externally sourced opportunities for first-in-class therapies. Loxo Onc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters